ConvaTec’s $1.8bn float bright spot in a subdued autumn market
Linklaters and Freshfields Bruckhaus Deringer are advising on medical products company ConvaTec’s anticipated $1.8bn initial public offering (IPO).
Subscriber Access
You must be logged in to view full premium content.
